UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer
Executive Summary
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
You may also be interested in...
UK Shares How Its Medtech Regs Already Diverge From The EU: COVID-19 Marks The Start
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
UK Allows Non-CE-Marked Devices On Market Under Exceptional Use Route
The UK government has launched an initiative to get non-medtech manufacturers involved in the production of ventilators. But it looks like they will be scrapped after the emergency has passed.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.